These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 20519717)

  • 21. Predicting the outcome of phase III trials using phase II data: a case study of clinical trial simulation in late stage drug development.
    De Ridder F
    Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):235-41. PubMed ID: 15733220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity.
    Stearns V; Gallagher A; Kleer CG; Singh B; Freedman M; Haddad BR; Isaacs C; Warren R; Brown M; Cullen J; Trock B; Hayes DF
    Clin Cancer Res; 2004 Dec; 10(24):8332-40. PubMed ID: 15623610
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel designs and end points for phase II clinical trials.
    Adjei AA; Christian M; Ivy P
    Clin Cancer Res; 2009 Mar; 15(6):1866-72. PubMed ID: 19276272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The ethics of phase 0 oncology trials.
    Abdoler E; Taylor H; Wendler D
    Clin Cancer Res; 2008 Jun; 14(12):3692-7. PubMed ID: 18559585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [An index of understanding randomised clinical trials in oncology].
    Leroy T; Christophe V; Penel N; Antoine P; Vanlemmens L; Reich M; Clisant S
    Bull Cancer; 2009 Jun; 96(6):741-50. PubMed ID: 19467958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical trials in New Zealand--treading water in the knowledge wave?
    Jull A; Wills M; Scoggins B; Rodgers A
    N Z Med J; 2005 Aug; 118(1221):U1638. PubMed ID: 16138176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical trials and biomarker development with molecularly targeted agents and radiotherapy.
    Dhani N; Siu LL
    Cancer Metastasis Rev; 2008 Sep; 27(3):339-49. PubMed ID: 18379730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical trial design in metastatic breast cancer: a commentary.
    Levine M
    Can J Oncol; 1995 Dec; 5 Suppl 1():40-2. PubMed ID: 8853523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A clinical development paradigm for cancer vaccines and related biologics.
    Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
    J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. "Sufficient life expectancy": an amazing inclusion criterion in cancer phase II-III trials.
    Penel N; Clisant S; Lefebvre JL; Adenis A
    J Clin Oncol; 2009 Sep; 27(26):e105. PubMed ID: 19667257
    [No Abstract]   [Full Text] [Related]  

  • 32. Bazedoxifene: a third-generation selective estrogen receptor modulator for treatment of postmenopausal osteoporosis.
    Stump AL; Kelley KW; Wensel TM
    Ann Pharmacother; 2007 May; 41(5):833-9. PubMed ID: 17426077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The good assessment criteria in oncology is not still the one we think].
    Bastide C
    Prog Urol; 2013 Nov; 23(15):1224. PubMed ID: 24183080
    [No Abstract]   [Full Text] [Related]  

  • 34. EMA must improve the quality of its clinical trial reports.
    Barbui C; Baschirotto C; Cipriani A
    BMJ; 2011 May; 342():d2291. PubMed ID: 21613341
    [No Abstract]   [Full Text] [Related]  

  • 35. Correction: SITC clinical Immuno-Oncology network (SCION) commentary on measurement and interpretation of essential biomarkers in early clinical trials.
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38531665
    [No Abstract]   [Full Text] [Related]  

  • 36. Trends in the global immuno-oncology landscape.
    Tang J; Pearce L; O'Donnell-Tormey J; Hubbard-Lucey VM
    Nat Rev Drug Discov; 2018 Dec; 17(12):922. PubMed ID: 30361553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disparity in the selection of patients in clinical trials.
    Habibzadeh F
    Lancet; 2022 Mar; 399(10329):1048. PubMed ID: 35279257
    [No Abstract]   [Full Text] [Related]  

  • 38. Redefining the primary objective of phase I oncology trials.
    Ratain MJ
    Nat Rev Clin Oncol; 2015 Mar; 12(3):126. PubMed ID: 25200413
    [No Abstract]   [Full Text] [Related]  

  • 39. How to Develop and Implement Computerized Comprehensive Clinical Database in Oncology-the Way Forward.
    Deo SVS; Bansal B; Kumar S
    Indian J Surg Oncol; 2023 Mar; 14(1):1-5. PubMed ID: 36891426
    [No Abstract]   [Full Text] [Related]  

  • 40. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy.
    Montero J; Sarosiek KA; DeAngelo JD; Maertens O; Ryan J; Ercan D; Piao H; Horowitz NS; Berkowitz RS; Matulonis U; Jänne PA; Amrein PC; Cichowski K; Drapkin R; Letai A
    Cell; 2015 Feb; 160(5):977-989. PubMed ID: 25723171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.